Battelle has again been chosen to protect our warfighters and the general public against dangerous infectious disease and chemical threats under a new contract award. The research, which is funded by the U.S. Army Joint Program Executive Office, is part of an OASIS contract mechanism that is worth up to $59 million, including all options, over the next five years.
For decades, Battelle has conducted research designed to protect the military from these threats. Frequently, the vaccines and therapeutics developed and tested on these programs then make their way to protecting the civilian populace.
Work covered by this latest contract includes development of vaccines for potentially weaponized threats such as plague, botulinum, equine encephalitis, and filovirus, as well as medical countermeasures against multiple nerve agents and poisonous toxins used in chemical warfare.
“We’re proud of the work we do at Battelle to protect people from threats like the Ebola and Zika viruses and ricin,” said Julie Swick, general manager for Battelle’s Life Sciences Research group. “Our dedicated employees come into work every day knowing they are contributing solutions to important, worldwide problems.”